Edgewise Therapeutics, Inc.
EWTX
$44.17
$0.992.29%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -197.22M | -176.01M | -167.80M | -157.24M | -150.70M |
| Total Depreciation and Amortization | 2.33M | 2.30M | 2.27M | 2.32M | 2.35M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.68M | 27.65M | 27.09M | 23.83M | 21.44M |
| Change in Net Operating Assets | 5.83M | -2.44M | -5.37M | -1.09M | 2.13M |
| Cash from Operations | -158.38M | -148.49M | -143.82M | -132.18M | -124.78M |
| Capital Expenditure | -454.00K | -472.00K | -256.00K | -457.00K | -888.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 166.86M | -73.78M | -32.53M | -61.17M | -71.10M |
| Cash from Investing | 166.40M | -74.26M | -32.79M | -61.63M | -71.98M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 20.89M | 206.00M | 196.09M | 195.01M | 196.90M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 38.00K | 0.00 | 0.00 | -214.00K |
| Cash from Financing | 20.89M | 206.04M | 196.09M | 195.01M | 196.68M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 28.92M | -16.71M | 19.48M | 1.20M | -81.00K |